
Opinion|Videos|December 4, 2024
Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)
Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
3
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5






